Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to p...

Full description

Saved in:
Bibliographic Details
Main Authors: Giuseppe Rosano, David Quek, Felipe Martínez
Format: Article
Language:English
Published: Radcliffe Medical Media 2020-11-01
Series:Cardiac Failure Review
Online Access:https://www.cfrjournal.com/articleindex/cfr.2020.23
Tags: Add Tag
No Tags, Be the first to tag this record!